Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients

Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.

Trial Details

NCT ID
NCT05636787
Phase
PHASE2
Sponsor
Insel Gruppe AG, University Hospital Bern
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Treosulfan
  • Melphalan
Locations (sample)
  • Bern, Switzerland|46.94809,7.44744

Key Eligibility Criteria

  • Eligible are myeloma patients after standard first-line induction treatment. Additional induction regimens in refractory myeloma patients are allowed.
  • Patients must be considered fit for subsequent consolidation with high-dose chemotherapy with autologous stem cell transplantation.
  • Patients must be aged 18-75 years.
  • Patients must have an ECOG \<3.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →